Apollomics (NASDAQ:APLM) Upgraded at Wall Street Zen

Apollomics (NASDAQ:APLM) was upgraded by investment analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report released on Saturday.

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Apollomics in a research note on Monday. One analyst has rated the stock with a Sell rating, According to MarketBeat, the stock presently has a consensus rating of “Sell”.

Apollomics Trading Up 11.3%

Shares of Apollomics stock opened at $16.83 on Friday. The stock has a fifty day simple moving average of $18.22 and a 200 day simple moving average of $11.86. Apollomics has a 12-month low of $3.66 and a 12-month high of $42.12.

Apollomics Company Profile

Apollomics, Inc, a clinical-stage biopharmaceutical company based in Palo Alto, California, focuses on the development of innovative targeted therapies and immuno-oncology agents for the treatment of cancer. The company’s research and development efforts center on small molecule inhibitors and monoclonal antibodies designed to address key pathways involved in tumor growth and immune evasion. Its lead asset, dalpiciclib (formerly SHP654), is a selective oral CDK4/6 inhibitor in Phase III trials for metastatic breast cancer, and Apollomics holds a number of additional early-stage programs targeting solid tumors and hematologic malignancies.

Founded in 2015, Apollomics has established research and clinical collaboration networks across North America, China and Europe.